Hatteras Venture Partners has announced the final closings of Hatteras Venture Partners VII (HVP VII) and Hatteras Opportunity Fund I, LP (HOF I), securing over $200 million in capital commitments from limited partners. This milestone coincides with Hatteras’s investment in its 100th portfolio company and marks 25 years of developing transformational companies in the field of human medicine.
Founded in 2000 with capital of just $2.93 million, Hatteras now manages over $900 million, focusing on seed- and early-stage companies in the health innovation sectors, including biotechnology and health technology.
Highlights of notable companies Hatteras has supported include:
- HistoSonics: Developed a groundbreaking ultrasound technology for liver tumors, received FDA approval in 2023, and was recently acquired for $2.25 billion.
-
Kymera Therapeutics: A leader in targeted protein degradation, participated in key funding rounds and went public in 2020, now valued at over $3 billion.
-
G1 Therapeutics: Created in 2017, a chemotherapy protective drug, and was acquired by Pharmacosmos in 2024 after achieving a market cap exceeding $2 billion.
-
Jumo Health: Transitioned to a digital health education platform and was acquired in 2024, providing a more than 7x return for Hatteras.
-
Iris Healthcare: Developed advanced care planning programs, acquired by Aledade in 2023, resulting in over 7x returns.
-
Asthmatx: Established a pioneering asthma treatment device, sold to Boston Scientific in 2010 for $194 million plus earnouts.
-
Synthematix: Hatteras’s first investment, which focused on electronic lab notebooks, sold in 2005 for $13 million plus earnouts.
Hatteras has also made two key promotions: Ben Scruggs, Ph.D., becomes Partner, focusing on biopharmaceuticals and leading Altis Biosystems, while Lauren Flickinger, now a Partner, oversees the Hatteras-managed Pisgah Fund in Asheville, N.C., and plays a significant role in health technology investments.
KEY QUOTES:
“Last week, our portfolio company, HistoSonics, announced its strategic acquisition in a landmark transaction. Across 100 portfolio companies and 25 years, we’ve had our share of exhilarating wins like this, along with heartbreaking disappointments. What has been most gratifying in this journey is the relationships we have made with scholarly innovators, committed entrepreneurs, and resilient co-investors. We look forward to continuing to invest in transformative life sciences companies disrupting the status quo in healthcare and accelerating the pace of innovation.”
Clay Thorp, General Partner of Hatteras Venture Partners
“Ben and Lauren possess the values, instincts, and tenacity we need to lead Hatteras into the future. The opportunity for them to lead new deals and harvest existing investments in HVP VII is tremendous, and I look forward to continuing our work together as they step into these expanded leadership roles.”
John Crumpler, Co-Founder and General Partner of Hatteras Venture Partners
